XBB.1.5疫苗与既往感染对KP.3症状性感染的保护作用
在东京1826名接种≥3剂mRNA疫苗的医院职工中,前瞻性分析XBB.1.5疫苗和既往感染对KP.3波症状性感染的保护。XBB.1.5疫苗接种未显示可测量保护(4%,95%CI -88至51),既往感染保护随近期性增加,JN.1波感染达89%(95%CI 52至97)。
要点
- XBB.1.5疫苗接种约7个月后对KP.3症状性感染无 measurable 保护
- 既往感染保护随感染时间越近而增强,JN.1波感染保护达89%
- 近期JN.1感染诱导的KP.3中和活性显著高于XBB.1.5疫苗接种
核心结论
- 在KP.3波期间,约7个月前接种的XBB.1.5疫苗未提供可测量的中和活性或症状性感染保护。
- 既往SARS-CoV-2感染,尤其是近期JN.1波感染,提供实质性的中和滴度和保护。
研究设计与样本
- 前瞻性队列研究,纳入1826名东京三级医院职工,均已接种≥3剂COVID-19 mRNA疫苗,2024年6月提供血样。
- 嵌套病例对照分析,比较病例与1:1倾向评分匹配对照的感染前活病毒KP.3.3中和抗体滴度。
主要发现
- XBB.1.5疫苗接种对症状性感染的保护为4%(95%CI -88至51)。
- 既往感染保护:前奥密克戎XBB波26%(95%CI -26至56),奥密克戎XBB波44%(95%CI 2至68),奥密克戎JN.1波89%(95%CI 52至97)。
- 病例感染前KP.3.3中和滴度 tendency 低于匹配对照(GMT比值0.68,95%CI 0.35至1.33)。
- KP.3.3中和活性仅被XBB.1.5疫苗接种 modestly 提升,近期JN.1感染后显著更高。
临床怎么用
- 在更新疫苗不可及时,应关注近期感染史对人群保护的潜在贡献。
- XBB.1.5疫苗接种后约7个月对KP.3症状性感染保护有限,需考虑疫苗更新策略。
局限性
- 研究人群为医院职工,结果外推需谨慎。
- 中和抗体滴度比较的置信区间较宽,需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Data are limited on the protection of Omicron XBB.1.5 vaccine, previous infection, and their induced neutralizing antibodies against Omicron KP.3 infection. METHODS: Among 1826 tertiary hospital staff in Tokyo who had received three or more doses of COVID-19 mRNA vaccines and provided blood samples in June 2024, we prospectively examined the associations of XBB.1.5 vaccination and previous infection (classified by the timing of the last infection as pre-Omicron XBB, Omicron XBB, or Omicron JN.1 waves) with the risk of symptomatic SARS-CoV-2 infection during the Omicron KP.3 wave (June to September 2024). In a nested case-control analysis, we compared pre-infection live-virus KP.3.3-neutralizing antibody titers between cases and 1: 1 propensity-score matched controls. RESULTS: XBB.1.5 vaccination was not associated with measurable protection against symptomatic infection (4%, 95% CI, -88 to 51). Previous infection conferred protection that increased with its recency: 26% (95% CI, -26 to 56) for pre-Omicron XBB, 44% (95% CI, 2 to 68) for Omicron XBB, and 89% (95% CI, 52 to 97) for Omicron JN.1 waves. Pre-infection KP.3.3-neutralizing titers tended to be lower in cases than in matched controls (GMT ratio 0.68, 95% CI, 0.35 to 1.33); KP.3.3-neutralizing activity was only modestly elevated by XBB.1.5 vaccination but markedly higher after recent JN.1 infection. CONCLUSIONS: During the Omicron KP.3 wave, when an updated vaccine was unavailable, XBB.1.5 vaccination administered approximately 7 months earlier conferred no measurable neutralizing activity or protection against symptomatic KP.3 infection. Previous SARS-CoV-2 infection, particularly recent JN.1-wave infection, affords substantial neutralizing titers and protection.
引用
- Yamamoto S, Matsuda K, Maeda K, et al. Protection of Omicron XBB.1.5 vaccine, previous infection, and their induced neutralizing antibodies against symptomatic SARS-CoV-2 infection during Omicron KP.3 wave. Vaccine. 2026. PMID: 42879903. doi:10.1016/j.vaccine.2026.129242
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。